API-192

N/A

Report date: 2023/12/06 17:34:13

Base Information

Drug NameAPI-192

Drug Alias NameAllogeneic CD19/20 CAR-NKT Product(Appia Bio)API-192

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cell replacementsB-lymphocyte antigen CD19 modulatorsB-lymphocyte antigen CD20 modulators

TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAppia Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesAppia Bio Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A